Hologic (HOLX) is a publicly traded Healthcare sector company. As of May 21, 2026, HOLX trades at $76.01 with a market cap of $16.97B and a P/E ratio of 31.41. HOLX moved +0.00% today. Year to date, HOLX is +2.52%; over the trailing twelve months it is +23.21%. Its 52-week range spans $51.90 to $84.39. Analyst consensus is hold with an average price target of $79.00. Rallies surfaces HOLX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Hologic Q1 Diagnostics Revenue Dips 1.3% to $464.4M as Molecular Sales Drop: Hologic’s Diagnostics revenue in Q1 fiscal 2026 fell 1.3% year-over-year to $464.4 million, led by a 3.5% decline in Molecular Diagnostics from weaker COVID-19 and legacy STI test sales. FDA approval for the Aptima HPV Assay and expanded CE marking for the Genius System strengthen its screening and imaging offerings.
| Metric | Value |
|---|---|
| Price | $76.01 |
| Market Cap | $16.97B |
| P/E Ratio | 31.41 |
| EPS | $2.42 |
| Dividend Yield | 0.00% |
| 52-Week High | $84.39 |
| 52-Week Low | $51.90 |
| Volume | 102.03M |
| Avg Volume | 0 |
| Revenue (TTM) | $4.13B |
| Net Income | $543.80M |
| Gross Margin | 51.47% |
42 analysts cover HOLX: 0 strong buy, 18 buy, 23 hold, 1 sell, 0 strong sell. Consensus rating is hold. Average price target: $79.00.